麻豆传媒

At the American Society of Clinical Oncology annual meeting, several important abstracts on endometrial cancer were presented, introducing some novel therapies that physicians are hoping will eventually enter the treatment landscape for these patients.

In this exclusive 麻豆传媒 video, , medical director of the Cedars-Sinai Cancer Clinical Trials Office in Los Angeles, touched on some of the key emerging data she is most excited about.

Following is a transcript of her remarks:

The treatments that I am most excited to hear about in the coming year, and that I think may be the most impactful, are the antibody-drug conjugates -- specifically those with targets in endometrial cancer.

We heard a little bit of data about the new HER2 antibody drug conjugate, which had some really remarkable results in both ovarian, endometrial, and cervical cancers that were HER2-positive. However, those numbers were exceedingly small, with only two or three patients per arm. So that data needs more time to mature. We need more patients to be treated to really understand.

I'm very excited to hear some more about folate receptor, which is also expressed in some endometrial cancers. So some of those new folate receptor antibody drug conjugates will have data coming out probably in the next year. And hopefully we'll see some responses there, which just present another mechanistic line of therapy for these patients, not all of whom will respond to standard of care.

And then obviously we're really and where this continues to take us. Obviously for the microsatellite instability patients with endometrial cancer, immunotherapy with checkpoint inhibitors has really dramatically changed the landscape. But there are always those patients for whom these drugs don't work or they fail over time. And so we want to find those combinations, those novel therapies or rescue therapies, that may reverse those resistances and really provide our patients with some long-term time with their families.

Comment